Separate terms with OR to return results that match either term.
 
Clear All

611 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year (Ascending) FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J0642 Levoleucovorin Khapzory 0.5mg Ancillary Therapy Chemoprotective Antidote No 2018 Oct. 1, 2019 In Use
J9198 Gemcitabine HCl Infugem 100mg Chemotherapy Antimetabolite Pyrimidine Analog No 2018 July 1, 2020 In Use
NA Apalutamide Erleada 60mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2018 In Use
NA Binimetinib Mektovi 15mg Chemotherapy MEK Inhibitor MEK 1/2 Yes 2018 In Use
NA Dacomitinib Vizimpro 15mg, 30mg, 45mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2018 In Use
NA Duvelisib Copiktra 15mg, 25mg Chemotherapy Enzyme Inhibitor PI3K Yes 2018 In Use
NA Encorafenib Braftovi 50mg, 75mg Chemotherapy BRAF Inhibitor V600E Yes 2018 In Use
NA Gilteritinib Xospata 40mg Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2018 In Use
NA Glasdegib Daurismo 25mg, 100mg Chemotherapy Hedgehog Pathway Inhibitor SMO Yes 2018 In Use
NA Ivosidenib Tibsovo 250mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2018 In Use
NA Larotrectinib Vitrakvi 25mg, 100mg 20mg/ml Chemotherapy Tyrosine Kinase Inhibitor TRK Yes 2018 In Use
NA Lorlatinib Lorbrena 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Yes 2018 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
NA Talazoparib Talzenna 0.25mg, 1mg Chemotherapy Enzyme Inhibitor PARP Yes 2018 In Use
Q5111 Pegfilgrastim-cbqv Udenyca 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 2019 Jan. 1, 2019 In Use
J9356 Trastuzumab and Hyaluronidase-oysk Herceptin hylecta 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 July 1, 2019 In Use
Q5117 Trastuzumab-anns Kanjinti 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Oct. 1, 2019 In Use
Q5118 Bevacizumab-bvcr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct. 1, 2019 In Use
C9058 Pegfilgrastim-bmez Ziextenzo 0.5mg Ancillary Therapy immunomodulatorne Granulocyte Colony Stimulating Factor No 2019 March 31, 2020 July 1, 2020 No Longer Used
J0896 Luspatercept Reblozyl 0.25mg Ancillary Therapy Erythropoiesis-Stimulating Agent No 2019 July 1, 2020 In Use
J9177 Enfortumab vedotin-ejfv Padcev 0.25mg Immunotherapy Drug Antibody Conjugate Nectin-4 No 2019 July 1, 2020 In Use
J9358 Fam-trastuzumab deruxtecan-nxki Enhertu 1mg Immunotherapy Drug Antibody Conjugate HER2, topoisomerase, tetrapeptide No 2019 July 1, 2020 In Use
Q5119 Rituximab-pvvr Ruxience 10mg Immunotherapy Monoclonal Antibody CD20 No 2019 July 1, 2020 In Use
Q5120 Pegfilgratim-bmez Ziextenzo 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2019 July 1, 2020 In Use
NA Alpelisib Piqray 200mg Chemotherapy Enzyme Inhibitor PI3K Yes 2019 In Use

Found 611 results in 3 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.